Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests quick, portable tools to diagnose asthma without hospital visits

NCT ID NCT05992519

Diagnosis Sponsor: Université de Sherbrooke Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two simple tests—a breath test (FeNO) and a blood test (eosinophil count)—to see if they can diagnose asthma more easily than current hospital-based breathing tests. Researchers studied 123 people aged 12 and older with suspected asthma. The goal was to find out if these portable tests can reliably detect asthma and airway inflammation, potentially speeding up diagnosis and reducing the need for complex hospital procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

123 people

The number who actually took part.

Started

Nov 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study has a collaboration agreement with the respiratory physiology service. In this context, a research invitation letter will be sent with confirmation of the appointment. The letter indicates that participation is voluntary and provides the expected length of the appointment (20-30 minutes), a QR code referring them to an online version of the Information and Consent Form (ICF), and a cell phone number and email address for the research team, with a phone number for individuals to state their refusal to be contacted. In the week preceeding the challenge, the clinical inhalation therapist will call non-objecting pre-screened patients to discuss the project and plan the study visit.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * aged ≥ 12 years who have symptoms suggestive of asthma, * referred by their primary care provider (defined as a non-respirologist, non-allergist, non-otolaryngologist) using the CHUS suspected asthma decision-making algorithm. Under that algorithm, patients have non-diagnostic pre- and post-bronchodilator spirometry and no contraindications to a methacholine challenge. * Free and informed consent must be given by the patient (and their legal guardian, if applicable). Exclusion Criteria: * Use of an inhaled or systemic corticosteroid in the previous 48 hours; * Smoking in the previous 6 hours; history of viral and/or bacterial respiratory infection in the past 4 weeks; * major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1/FVC \<0.7) and iii) a smoking history of \>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma childhood onset asthma disease Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Asthma in children Diagnosis Inflammation

Contacts and locations

Locations

  • Centre de Recherche du CHUS

    Sherbrooke, Quebec, J1H5N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.